Genetic Variant of Vascular Endothelial Growth Factor (VEGF)-A rs699947 is Associated with Preeclampsia

Anggelia Puspasari; Rina Nofri Enis; Herlambang Herlambang

doi:10.21705/mcbs.v6i2.241

Genetic Variant of Vascular Endothelial Growth Factor (VEGF)-A rs699947 is Associated with Preeclampsia

Anggelia Puspasari, Rina Nofri Enis, Herlambang Herlambang

Abstract

Background: Preeclampsia remains as the leading cause of maternal-neonatal mortality and morbidity worldwide. Vascular endothelial growth factor A (VEGF-A) is a proangiogenic factor related to endothelial dysfunction and plays an important role in the preeclampsia pathophysiology. Genetic variants of VEGF-A are associated with VEGF-A expression and preeclampsia risk, however there are still inconsistent results between different populations. The aim of this study was to determine the association of this genetic variant as preeclampsia risk factor.

Materials and methods: A cross-sectional study was performed with 76 pregnant women (29 preeclampsia and 47 normotensive) Jambi-Malay ethnic subjects. Sample DNA was extracted from subject’s blood. To determine the genotype, one-step tetra amplification refractory mutation system (ARMS) polymerase chain reaction (PCR) method for VEGF-A rs699947 C/A was used.

Results: We found that pregnant woman with AC genotype (p-value=0.045; OR=2.76 ; 95% CI=1.01-7.58) and AA genotype (p-value=0.026; OR=12.44; 95% CI=1.23-126.18) had higher risk of preeclampsia than the CC genotype.

Conclusion: Genetic variant VEGF-A rs699947 C/A is associated with preeclampsia. The AC and AA genotype is the risk genotype for preeclampsia in Jambi-Malay ethnics.

Keywords: preeclampsia, VEGF-A, genetic variant, Jambi-Malay, Indonesia

Full Text:

PDF

References

American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013; 122(5): 1122–31, CrossRef.

Sammour MB, el-Kabarity H, Fawzy MM, Schindler AE. Prevention and treatment of pregnancy-induced hypertension (preeclampsia) with progestogens. J Steroid Biochem. 2005; 97(5): 439-40, CrossRef.

Zhou L, Hui X, Yuan H, Liu Y, Wang Y. Combination of genetic markers and age effectively facilitates the identification of people with high risk of preeclampsia in the Han Chinese population. Biomed Res Int. 2018; 2018: 4808046, CrossRef.

Michita RT, Kaminski VL, Chies JAB. Genetic variants in preeclampsia: Lessons from studies in Latin-American populations. Front Physiol. 2018; 9: 1771, CrossRef.

Buurma AJ, Turner RJ, Driessen JHM, Mooyaart AL, Schoones JW, Bruijn JA, et al. Genetic variants in pre-eclampsia: A meta-analysis. Hum Reprod Update. 2013; 19(3): 289–303, CrossRef.

Karumanchi SA. Angiogenic factors in preeclampsia: From diagnosis to therapy. Hypertension. 2016; 67(6): 1072–9, CrossRef.

Gathiram P, Moodley J. Pre-eclampsia: Its pathogenesis and pathophysiology. Cardiovasc J Afr. 2016; 27(2): 71–8, CrossRef.

Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: Updates in pathogenesis, definitions, and guidelines. Clin J Am Soc Nephrol. 2016; 11(6): 1102-13, CrossRef.

Eddy AC, Bidwell GL, George EM. Pro-angiogenic therapeutics for preeclampsia. Biol Sex Differ. 2018; 9: 36, CrossRef.

Sandrim VC, Palei ACT, Cavalli RC, Araújo FM, Ramos ES, Duarte G, et al. Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. Mol Hum Reprod. 2009; 15(2): 115–20, CrossRef.

El-Sonbati AZ, El-Baz RA, Saad EA, El-Zekred AS. Vascular endothelial growth factor VEGF G/C 405 and C/A 2578 gene polymorphisms in cases with pre-eclampsia. Int J Pharm Pharm Sci. 2014; 6(10): 281–4, article.

Song GG, Kim JH, Lee YH. Associations between vascular endothelial growth factor gene polymorphisms and pre-eclampsia susceptibility: A meta-analysis. Immunol Invest. 2013; 42(8): 749–62, CrossRef.

Qi W, Piao S, Li C, Zhang L. Association of VEGF +936C/T, -634G/C, -2578C/A and -1154G/A polymorphisms with preeclampsia risk in Chinese pregnant women. Int J Clin Exp Med. 2017; 10(11): 15391–9, article.

Cheng D, Hao Y, Zhou W, Ma Y. Vascular endothelial growth factor +936C/T, -634G/C, -2578C/A, and -1154G/A polymorphisms with risk of preeclampsia: A meta-analysis. PLoS One. 2013; 8(11): e78173, CrossRef.

Al Balawi IA, Mir R, Abu-Duhier FM. Potential impact of vascular endothelial growth factor gene variation (-2578C > A) on breast cancer susceptibility in Saudi Arabia: A case-control study. Asian Pac J Cancer Prev. 2018; 19(4): 1135–43, CrossRef.

Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019; 124(7): 1094-112, CrossRef.

Bdolah Y, Elchalal U, Natanson-Yaron S, Yechiam H, Bdolah-Abram T, Greenfield C, et al. Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. Hypertens Pregnancy. 2014; 33(2): 250–9, CrossRef.

Pragitara CF, Etika R, Herawati L, Aditiawarman A. Risks of preterm birth and low Apgar score among preeclamptic women. Jurnal Kedokteran dan Kesehatan Indonesia. 2020; 11(1): 6–17, article.

Safitri A, Djaiman SPH. Hubungan hipertensi dalam kehamilan dengan kelahiran prematur: Metaanalisis. Media Penelitian dan Pengembangan Kesehatan. 2021; 31(1): 27–38, CrossRef.

Rasmussen S, Ebbing C, Irgens LM. Predicting preeclampsia from a history of preterm birth. PLoS One. 2017; 12(7): e0181016, CrossRef.

Matyas M, Hasmasanu M, Silaghi CN, Samasca G, Lupan I, Orsolya K, et al. Early preeclampsia effect on preterm newborns outcome. J Clin Med. 2022; 11(2): 452, CrossRef.

Bernardes TP, Mol BW, Ravelli ACJ, van den Berg P, Boezen HM, Groen H. Early and late onset pre-eclampsia and small for gestational age risk in subsequent pregnancies. PLoS One. 2020; 15(3): e0230483, CrossRef.

Chisholm KM, Norton ME, Penn AA, Heerema-McKenney A. Classification of preterm birth with placental correlates. Pediatr Dev Pathol. 2018; 21(6): 548–60, CrossRef.

Kongwattanakul K, Saksiriwuttho P, Chaiyarach S, Thepsuthammarat K. Incidence, characteristics, maternal complications, and perinatal outcomes associated with preeclampsia with severe features and HELLP syndrome. Int J Women’s Health. 2018; 10: 371–7, CrossRef.

Ehnert S, Linnemann C, Braun B, Botsch J, Leibiger K, Hemmann P, et al. One-step ARMS-PCR for the detection of SNPs — using the example of the PADI4 gene. Methods Protoc. 2019; 2(3): 63, CrossRef.

Medrano RF, de Oliveira CA. Guidelines for the tetra-primer ARMS–PCR technique development. Mol Biotechnol. 2014; 56(7): 599-608, CrossRef.

Alidoosti M, Shanaki M, Mahdavi A, Mohammadtaghvaei N. Association between vascular endothelial growth factor plasma levels and rs699947 polymorphism and coronary collateral vessel formation. J Tehran Heart Cent. 2019; 14(3): 121–7, CrossRef.

Wang A, Rana S, Karumanchi SA. Preeclampsia: The role of angiogenic factors in its pathogenesis. Physiology (Bethesda). 2009; 24: 147–58, CrossRef.

Tandon V, Hiwale S, Amle D, Nagaria T, Patra PK. Assessment of serum vascular endothelial growth factor levels in pregnancy-induced hypertension patients. J Pregnancy. 2017; 2017: 3179670, CrossRef.

Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010; 5: 173-92, CrossRef.

Papazoglu D, Galazios G, Koukourakis MI, Panagopoulos I, Kontomanolis EN, Papatheodorou K, et al. Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod. 2004; 10(5): 321–4, CrossRef.

DOI: https://doi.org/10.21705/mcbs.v6i2.241

Copyright (c) 2022 Cell and BioPharmaceutical Institute